Summit Therapeutics Inc. Research And Development Expense
Summit Therapeutics Inc. (SMMT) reported Research And Development Expense of GBP 9.75 million for the 3-month period ending 2020-03-31, per its 6-K filed 2020-06-02.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2020-06-02
- Summit Therapeutics Inc. research and development expense for the quarter ending 2020-03-31 was 9.75M GBP, a 17.85% increase year-over-year.
- Summit Therapeutics Inc. research and development expense for the quarter ending 2019-10-31 was 7.22M GBP, a 11.85% decline year-over-year.
- Summit Therapeutics Inc. research and development expense for the quarter ending 2019-07-31 was 9.22M GBP, a 6.47% decline year-over-year.
- Summit Therapeutics Inc. research and development expense for the quarter ending 2019-04-30 was 8.27M GBP, a 28.62% decline year-over-year.
| Period end | Research And Development Expense 3 month | Research And Development Expense 3 month as first filed | Research And Development Expense 6 month | Research And Development Expense 6 month as first filed | Research And Development Expense 9 month | Research And Development Expense 9 month as first filed | Research And Development Expense 11 month | Research And Development Expense 12 month | Research And Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2020-03-31 | 9.75M GBP 6-K · filed 2020-06-02 | ||||||||
| 2019-12-31 | 31.20M GBP 20-F · filed 2020-04-30 | ||||||||
| 2019-10-31 | 7.22M GBP 6-K · filed 2019-12-17 | 16.44M GBP derived: sum of 2 quarters · filed 2019-12-17 | 24.71M GBP 6-K · filed 2019-12-17 | ||||||
| 2019-07-31 | 9.22M GBP 6-K · filed 2019-10-11 | 17.49M GBP 6-K · filed 2019-10-11 | |||||||
| 2019-04-30 | 8.27M GBP 6-K · filed 2019-06-12 | ||||||||
| 2019-03-31 | 8.69M GBP 6-K · filed 2020-06-02 | ||||||||
| 2019-01-31 | 9.54M GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | 17.74M GBP derived: sum of 2 quarters · filed 2020-04-30 | 27.59M GBP derived: sum of 3 quarters · filed 2020-04-30 | 39.18M GBP 20-F · filed 2020-04-30 | 39.17M GBP 20-F · filed 2019-03-29 | ||||
| 2018-10-31 | 8.20M GBP 6-K · filed 2019-12-17 | 8.20M GBP 6-K · filed 2018-12-11 | 18.05M GBP derived: sum of 2 quarters · filed 2019-12-17 | 29.64M GBP 6-K · filed 2019-12-17 | 29.63M GBP 6-K · filed 2018-12-11 | 39.55M GBP derived: sum of 4 quarters · filed 2020-04-30 | |||
| 2018-07-31 | 9.85M GBP 6-K · filed 2019-10-11 | 9.47M GBP 6-K · filed 2018-09-20 | 21.44M GBP 6-K · filed 2019-10-11 | 20.72M GBP 6-K · filed 2018-09-20 | 31.36M GBP derived: sum of 3 quarters · filed 2020-04-30 | 38.78M GBP derived: sum of 4 quarters · filed 2020-04-30 | |||
| 2018-04-30 | 11.59M GBP 6-K · filed 2019-06-12 | 11.25M GBP 6-K · filed 2018-06-05 | 21.50M GBP derived: sum of 2 quarters · filed 2020-04-30 | 28.93M GBP derived: sum of 3 quarters · filed 2020-04-30 | 35.53M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||||
| 2018-01-31 | 9.91M GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | 17.34M GBP derived: sum of 2 quarters · filed 2020-04-30 | 23.94M GBP derived: sum of 3 quarters · filed 2020-04-30 | 28.98M GBP 20-F · filed 2020-04-30 | 28.97M GBP 20-F · filed 2018-04-13 | ||||
| 2017-10-31 | 7.42M GBP 6-K · filed 2018-12-11 | 14.03M GBP derived: sum of 2 quarters · filed 2018-12-11 | 19.07M GBP 6-K · filed 2018-12-11 | ||||||
| 2017-07-31 | 6.61M GBP 6-K · filed 2018-09-20 | 11.64M GBP 6-K · filed 2018-09-20 | |||||||
| 2017-04-30 | 5.04M GBP 6-K · filed 2018-06-05 | ||||||||
| 2017-01-31 | 18.95M GBP 20-F · filed 2019-03-29 | ||||||||
| 2016-01-31 | 16.86M GBP 20-F · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |